EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors

EXELIXIS INC (NASDAQ:EXEL) stands out as a compelling pick for investors following Louis Navellier’s growth strategy. The company, focused on developing oncology treatments, meets multiple criteria from Navellier’s "Little Book That Makes You Rich," demonstrating strong earnings momentum, revenue growth, and profitability.

Why EXEL Fits the Little Book Strategy

• Earnings Revisions & Surprises: Analysts have raised EPS estimates for the next quarter by 15.4% over the past three months. EXEL has also beaten earnings expectations in each of the last four quarters, with an average surprise of 55.5%.
• Sales & Earnings Growth: Revenue grew 24.5% year-over-year, while quarterly sales increased 30.6%. EPS surged 205.6% over the past year, with quarterly EPS up 175%.
• Expanding Margins: Operating margin improved by 220% year-over-year, reflecting stronger profitability.
• Strong Cash Flow: Free cash flow grew 209.5% in the past year, indicating financial flexibility.
• High Return on Equity: With an ROE of 30.2%, EXEL efficiently generates profits from shareholder investments.

Fundamental Strengths

EXEL scores 8 out of 10 in our fundamental rating, excelling in profitability, financial health, and growth. The company has no debt, robust cash flow, and trades at reasonable valuations relative to industry peers.

For a deeper look, review the full fundamental analysis of EXEL.

Our Little Book Growth screener lists more stocks matching these criteria.

Disclaimer

This is not investing advice. Always conduct your own research before making investment decisions.